AZRX vs. DARE, VYNE, PMN, LPCN, RNXT, EQ, BIVI, CLNN, BOLT, and LSTA
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Daré Bioscience (DARE), VYNE Therapeutics (VYNE), ProMIS Neurosciences (PMN), Lipocine (LPCN), RenovoRx (RNXT), Equillium (EQ), BioVie (BIVI), Clene (CLNN), Bolt Biotherapeutics (BOLT), and Lisata Therapeutics (LSTA). These companies are all part of the "medical" sector.
AzurRx BioPharma (NASDAQ:AZRX) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Daré Bioscience's return on equity of 0.00% beat AzurRx BioPharma's return on equity.
Daré Bioscience received 129 more outperform votes than AzurRx BioPharma when rated by MarketBeat users. However, 74.26% of users gave AzurRx BioPharma an outperform vote while only 73.29% of users gave Daré Bioscience an outperform vote.
6.3% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 7.3% of AzurRx BioPharma shares are held by company insiders. Comparatively, 4.0% of Daré Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Daré Bioscience has higher revenue and earnings than AzurRx BioPharma. Daré Bioscience is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Daré Bioscience had 5 more articles in the media than AzurRx BioPharma. MarketBeat recorded 5 mentions for Daré Bioscience and 0 mentions for AzurRx BioPharma. Daré Bioscience's average media sentiment score of 0.23 beat AzurRx BioPharma's score of 0.00 indicating that Daré Bioscience is being referred to more favorably in the news media.
Daré Bioscience has a consensus target price of $54.00, suggesting a potential upside of 1,387.60%. Given Daré Bioscience's higher probable upside, analysts plainly believe Daré Bioscience is more favorable than AzurRx BioPharma.
AzurRx BioPharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.
Summary
Daré Bioscience beats AzurRx BioPharma on 11 of the 15 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
Free AZRX Stock Alerts